Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis ...Middle East

SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis...

Hence then, the article about bridge biotherapeutics announces the initiation of patient dosing in the proof of clinical principle study for bbt 401 an investigational drug for ulcerative colitis was published today ( Monday 14/06/2021 - 02:30 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis )

Also on site :

• 1971 Folk Classic, by 'Genius' Singer-Songwriter, Helped Define One of the 'Best Movies of the 21st Century'
• Don't Do This Before Your Next Blood Test, Doctors Warn
• Costco Shoppers Are Racing to Grab This Ultimate Home Organization Item Before It Sells Out